

# PRIOR AUTHORIZATION REQUEST

5 ( ) ( ) <b>(</b>	4.	<u>Livtencity</u>		
Patient Info	rmation:			
Name:				
Member ID:				
Address:				
City, State, Z	Zip:			
Date of Birth	:			
Prescriber I	nformation:			
Name:				
NPI:				
Phone Numb	per:			
Fax Number				
Address:				
City, State, Z	ip:			
	-			
Requested I	viedication			
Rx Name:				
Rx Strength				
Rx Quantity:				
Rx Frequency:				
Rx Route of				
Administration:				
Diagnosis and ICD Code:				
prescribed a m quantities can l Upon receipt	edication for your be provided. Plea of the completed	efit requires that we review certain requests for coverage with the proposition patient that requires Prior Authorization before benefit coverage or consecutive the following questions then fax this form to the toll-free of form, prescription benefit coverage will be determined based of the that supporting clinical documentation is required.	overage of number lis on the pla	f additiona sted below an's rules
	ne patient greater o, no further ques	than or equal to 12 year(s) of age? tions.]	Yes	No
[] C		or indication? fection (If checked, go to 3) no further questions)		
	ne patient's weigh o, no further ques		Yes	No
[No	ne patient post-tra te: This includes p t-solid organ trans	patients who are post-hematopoietic stem cell transplant (HSCT) or	Yes	No

If you have any questions, call: 1-888-258-8250

# PRIOR AUTHORIZATION REQUEST

	[If no, no further questions.]		
5	Has documentation been submitted to confirm that the patient has a diagnosis of cytomegalovirus infection/disease that is refractory to treatment with at least one of the following: cidofovir, foscarnet, ganciclovir, or valganciclovir, unless intolerant to all medications listed? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
6	Has documentation been submitted to confirm that the patient has failed to achieve GREATER THAN 1 log 10 decrease in cytomegalovirus (CMV) DNA level in whole blood or plasma after MORE THAN 14 days of treatment with AT LEAST 2 medications such as cidofovir, foscarnet, ganciclovir, or valganciclovir? ACTION REQUIRED: Submit supporting documentation.  [If no, no further questions.]	Yes	No
7	Is the requested medication being prescribed in conjunction with ganciclovir or valganciclovir? [If yes, no further questions.]	Yes	No
8	Does the requested dose exceed the Food and Drug Administration (FDA) approved label dosing for the indication? [If yes, no further questions.]	Yes	No
9	Does the patient have a diagnosis of cytomegalovirus (CMV) disease that involves the central nervous system, including CMV retinitis? [If yes, no further questions.]	Yes	No
10	Is the requested medication being prescribed by or in consultation with a hematologist, infectious diseases specialist, oncologist, or a transplant physician? [If no, no further questions.]	Yes	No
11	Does the prescriber attest that the medication is not being used for the prevention of cytomegalovirus (CMV) infection? [If no, no further questions.]	Yes	No
12	If the patient is not responding to treatment, does the provider agree to monitor cytomegalovirus (CMV) DNA levels and check for resistance?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:



### PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

## **FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.